Corbus Pharmaceuticals Holdings, Inc. Fair Value Disclosure
5. FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES
The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December 31, 2025 (in thousands):
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Assets: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash equivalents: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Money market funds |
|
$ |
23,037 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
23,037 |
|
Commercial paper |
|
|
— |
|
|
|
1,488 |
|
|
|
— |
|
|
|
1,488 |
|
Corporate debt securities |
|
|
— |
|
|
|
2,616 |
|
|
|
— |
|
|
|
2,616 |
|
Investments: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Commercial paper |
|
|
— |
|
|
|
33,846 |
|
|
|
— |
|
|
|
33,846 |
|
Corporate debt securities |
|
|
— |
|
|
|
100,931 |
|
|
|
— |
|
|
|
100,931 |
|
|
|
$ |
23,037 |
|
|
$ |
138,881 |
|
|
$ |
— |
|
|
$ |
161,918 |
|
The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values as of December 31, 2024 (in thousands):
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Assets: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash equivalents: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Money market funds |
|
$ |
12,151 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
12,151 |
|
Investments: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
U.S. Treasury securities |
|
|
— |
|
|
|
9,467 |
|
|
|
— |
|
|
|
9,467 |
|
U.S. government agency securities |
|
|
— |
|
|
|
22,093 |
|
|
|
— |
|
|
|
22,093 |
|
Corporate debt securities |
|
|
— |
|
|
|
100,304 |
|
|
|
— |
|
|
|
100,304 |
|
|
|
$ |
12,151 |
|
|
$ |
131,864 |
|
|
$ |
— |
|
|
$ |
144,015 |
|
Want the next Corbus Pharmaceuticals Holdings, Inc. fair value disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Corbus Pharmaceuticals Holdings, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 9, 2026 | Showing above |
| 2024 | Mar 11, 2025 | |
| 2023 | Mar 12, 2024 | |
| 2022 | Mar 7, 2023 | |
| 2021 | Mar 8, 2022 | |
| 2015 | Mar 28, 2016 | |
About Fair Value Disclosures
Fair value disclosures classify all assets and liabilities measured at fair value into a three-level hierarchy: Level 1 (quoted market prices), Level 2 (observable inputs like yield curves), and Level 3 (unobservable inputs requiring management estimates). The proportion of Level 3 assets directly reflects how much of the balance sheet depends on internal models rather than market evidence.
Key signals: a growing Level 3 balance relative to total fair-value assets increases valuation uncertainty and earnings volatility risk. Watch for transfers between levels — assets moving from Level 2 to Level 3 often signal deteriorating market liquidity. Unrealized gains and losses on Level 3 positions flow through earnings or other comprehensive income, so large swings deserve scrutiny. For financial institutions, examine the sensitivity disclosures that show how Level 3 valuations change under alternative assumptions. Compare the fair value of debt against its carrying amount to gauge hidden leverage.